Add BrightSurf on Google Email

Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis

Home | Story
2 institutional releases

Published in Journal of Clinical Investigation · View the paper (DOI)

Researchers developed a new combined therapy for multiple sclerosis, combining tolerogenic dendritic cells with Dimethyl Fumarate to restore immune balance. The treatment showed promise in preclinical studies, reducing symptoms in mice and potentially offering hope for patients worldwide.

Coverage from 2 institutions

  • New study finds a promising combined therapy for multiple sclerosis
    • Article 1 Josep Carreras Leukaemia Research Institute · Oct 2, 2024 · first to report
    • Article 2 Germans Trias i Pujol Research Institute · Oct 3, 2024